Hematología

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study of Entrectinib (RXDX-101) for the Treatment of Patients with Solid Tumors that have NTRK1/2/3, ROS1, or ALK Gene Rearrangements

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the response of entrectinib (RXDX-101) for the treatment of patients with solid tumors that have an NTRK1/2/3, ROS1, or ALK gene rearrangement.

2. Cutaneous Lymphoma Database

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

3. A Study of R-ICE and Lenalidomide for Treating Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and how well they work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement and that has not responded to previous treatment. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as R-ICE, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide with R-ICE may be a better treatment for patients with diffuse large B-cell lymphoma.

4. Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer

   Rochester, Minn.

   This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with gemcitabine hydrochloride in treating patients with a solid tumor that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and gemcitabine hydrochloride may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help gemcitabine hydrochloride work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet know whether giving gemcitabine hydrochloride with or without disulfiram is a better treatment for unresectable solid tumors or metastatic pancreatic cancer.

5. Development of Tissue Bank of Blood, Urine, and Bone Marrow from Patients with B-Chronic Lymphocytic Leukemia (B-CLL)

   Rochester, Minn.

   This study is being done to find biologic abnormalities in the lymphocyte cells of patients with CLL (Chronic Lymphocytic Leukemia). In order to validate these tests, cells from patients with CLL will be studied when the tests are ready in the laboratory. This study is also being done to learn more about the environmental and genetic factors that might be responsible for CLL. Finding such factors would help us understand the causes and possible prevention of this cancer.

6. A Study of Circulating Tumor DNA as a Biomarker of a Complete Response of Disease for Advanced Gastroesophageal Adenocarcinoma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate circulating tumor DNA as a potential biomarker for pre-surgery treatment response in patients who have esophageal cancer.

7. A Study of the Biology of Bone Marrow Plasma Cells

   Rochester, Minn.

   The purpose of this study is to learn more about the biology of plasma cells, by examining survival properties, Ig gene expression, cellular and molecular phenotype, the incidence of genetic abnormalities, and the profile of proteins essential for DNA repair in normal plasma cells.

8. A Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy in Combination with Dexamethasone, and in Combination with Dexamethasone and Daratumumab or Bortezomib in Subjects with Relapsed and Refractory Multiple Myeloma

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone. The study will consist of an escalating dose-escalation portion (Part 1) as well as an expansion of each cohort (ie, Cohort C: Monotherapy (MonoT) and Cohort D: Combination treatment with 2 drugs (DoubleT) at the recommended Phase 2 dose (RP2D) to further evaluate safety and estimate preliminary efficacy (Part 2).

9. A Study to Collect Data and Blood Samples from Mayo Patients Who have or are Suspected to have Amyloidosis, or Their Family Members, for Future Research

   Rochester, Minn.

   The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

10. Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

    Rochester, Minn., Scottsdale/Phoenix, Ariz.

    This is a phase I, multicenter, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).